bioRxivCancer BiologyPreprint
Quercetin Suppresses TNBC Cell by Targeting ORM2
Abstract
BackgroundTriple-negative breast cancer (TNBC) is known for its aggressive nature, and Quercetin (QUE) has shown potential anti-cancer effects. MethodsWe determined the IC50 of QUE for inhibiting cell viability in multiple TNBC, non-TNBC, and normal breast cell lines. We compared the expression of ORM2 in TNBC clinical samples and normal tissues. Additionally, we measured ORM2 expression in TNBC and normal breast cell lines. We determined the IC50 of QUE for inhibiting cell viability after ORM2 knockdown. An orthotopic implantation mice model was used to evaluate the treatment effect of QUE. We also conducted molecular docking and amino acid exchange validation to model the binding of QUE to ORM2. Furthermore, we performed a protein-protein interaction network analysis and GO enrichment analysis of differentially expressed genes associated with ORM2 in TNBC. ResultsQUE inhibited the viability of both TNBC and non-TNBC cell lines, but it was specifically associated with worse survival in TNBC patients. We observed higher expression of ORM2 in breast cancer cells compared to normal breast cells. Knockdown of ORM2 reduced the viability of TNBC cells. Treatment with QUE inhibited ORM2 expression and decreased viability in TNBC cells. In the animal model, QUE improved survival and downregulated ORM2 expression in tumors. Enrichment analysis provided insights into the potential functions of ORM2. ConclusionOur findings indicate that QUE directly inhibits TNBC cell viability through its interaction with ORM2. These results contribute to our understanding of the anti-cancer mechanisms of QUE in TNBC and highlight ORM2 as a potential therapeutic target.
- organism: human
- assay: proteomics
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Quercetin as a Bitter Taste Receptor Agonist with Anticancer Effects in Head and Neck Cancer Cells
Gavin Turner, Sarah M. Sywanycz, … Ryan M. Carey·NutrientsPeer-reviewed·Oct 14, 2025
- Thiosemicarbazone T2 suppresses WNT/β-catenin signaling and limits progression to invasive disease in a mouse intraductal model of triple-negative breast cancer
Aldana Sólimo, Marianela Sciacca, … Mariana Alejandra Callero·bioRxiv·Jun 9, 2026
- Inhibiting BCKDK in triple-negative breast cancer suppress protein translation, impair mitochondrial function, and potentiate doxorubicin cytotoxicity
D. Biswas, L. Slade, … T. Pulinilkunnil·bioRxiv·May 18, 2021
- The inhibitory effects of butein on cell proliferation and TNF-α-induced CCL2 release in racially different triple negative breast cancer cells
P. Mendonca, A. Horton, … K. F. A. Soliman·bioRxiv·Apr 1, 2019
- Repurposing Quetiapine as an Adjuvant Therapeutic Agent for Triple-Negative Breast Cancer
Ling He, Purva Joshi, … Frank Pajonk·Radiation ResearchPeer-reviewed·Apr 23, 2026
- 1,4-dihydroxy Quininib Attenuates Growth of Colorectal Cancer Cells and Xenografts and Regulates the TIE-2 Signaling Pathway in Patient Tumours
C. T. Butler, S. Kennedy, … B. N. Kennedy·bioRxiv·Dec 21, 2018